2.62

1.50% -0.04

Kiora Pharmaceuticals Inc (KPRX)

Overview News Price History Financials Discussions Forecast Stock Split

Kiora Pharmaceuticals Inc stock is traded at $2.62, with a volume of 2,490. It is down -1.50% in the last 24 hours and up +1.95% over the past month. Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Previous Close:

$2.66

Open:

$2.67

24h Volume:

2,490

Relative Volume:

0.10

Market Cap:

$11.59M

Revenue:

$20,000

Net Income/Loss:

$-11.06M

P/E Ratio:

-0.9209

EPS:

-2.8449

Net Cash Flow:

$-10.53M

1W Performance:

-1.50%

1M Performance:

+1.95%

6M Performance:

+25.36%

1Y Performance:

-5.76%

1-Day Range:

$2.62

$2.67

1-Week Range:

$2.53

$2.75

52-Week Range:

$1.7645

$2.95

Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile

Name

Kiora Pharmaceuticals Inc

Sector

Healthcare (1080)

Industry

Biotechnology (605)

Phone

858-224-9600

Address

169 SAXONY RD., ENCINITAS

Employee

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

KPRX's Discussions on Twitter

Compare KPRX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPRX Kiora Pharmaceuticals Inc	2.62	11.59M	20,000	-11.06M	-10.53M	-2.8449
VRTX Vertex Pharmaceuticals Inc	541.69	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	794.19	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,023.21	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.99	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	207.88	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Kiora Pharmaceuticals Inc Stock (KPRX) Latest News

Aug 20, 2026

Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Nigeria

Aug 19, 2026

Kiora Licenses KIO-301 Rights in South Korea - TipRanks

Aug 19, 2026

Kiora Pharmaceuticals Licenses KIO-301 South Korea Rights to Chong Kun Dang for $1 Million Upfront Plus Milestones and Royalties - kalkine.ca

Aug 19, 2026

Aug 17, 2026

Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis - Kalkine

Aug 17, 2026

Aug 14, 2026

Perceptive Advisors LLC Acquires New Position in Kiora Pharmaceuticals Inc (KPRX) - GuruFocus

Aug 14, 2026

ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants - Stock Titan

Aug 14, 2026

Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing - Stock Titan

Aug 14, 2026

Aug 11, 2026

KPRX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesReturn On Capital - Vinanet

Aug 11, 2026

Aug 10, 2026

Kiora Pharmaceuticals (KPRX) reports 9.99% stake held by Perceptive group - Stock Titan

Aug 10, 2026

Aug 08, 2026

Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com - Investing.com Nigeria

Aug 08, 2026

Kiora Pharmaceuticals advances retinal disease trials, secures $24M funding, expects data in 2027 - Pluang

Aug 08, 2026

Aug 07, 2026

Kiora Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2026

Kiora Pharmaceuticals Reports Q2 2026 Results, Advances KIO-301 and KIO-104 Trials With Runway Into Late 2028 - kalkine.ca

Aug 07, 2026

Aug 05, 2026

Kiora Pharmaceuticals (KPRX) Gains 2.83% as Shares Approach $2.67 ResistanceGap and Reverse - dars.gov.et

Aug 05, 2026

Aug 04, 2026

Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a shareEarnings Preview - TradingView

Aug 04, 2026

Jul 27, 2026